Safety of Long-Acting β-Agonists

  1. Mats Jacob Lindberg, MD, MHA
  1. From Institute for Rational Pharmacotherapy, Copenhagen, Denmark.

    TO THE EDITOR:

    The meta-analysis by Salpeter and colleagues (1) is interesting and important; however, I have 2 concerns. My first concern is about the trial inclusion in their …

    [Full Text of this Article]
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med November 7, 2006 vol. 145 no. 9 706-707
    1. » Excerpt
    2. Full Text
    3. Full Text (PDF)

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. December 1, 2009, 151 (11)
    1. Alert me to current issues